Brentuximab vedotin
Across both trials, the most common adverse reactions (≥20%), regardless of causality, were chemotherapy-induced peripheral neuropathy (a progressive, enduring and often irreversible tingling numbness, intense pain, and hypersensitivity to cold, beginning in the hands and feet and sometimes involving the arms and legs), neutropenia (an immune system impairment), fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, fever, rash, thrombocytopenia, cough and vomiting.[2] In January 2012, the FDA announced that because brentuximab vedotin had been linked with two cases of progressive multifocal leukoencephalopathy, they were requiring the addition of a black box warning to the drug label regarding this potential risk.[12][2] In August 2011, the US Food and Drug Administration (FDA) granted accelerated approval to the biologics license application (BLA) submitted by Seattle Genetics for the use of brentuximab vedotin[13] in the treatment of relapsed HL and ALCL.While this application was accepted, the committee noted that on the basis of inadequate cost-benefit, the medicine would not be made available more generally for the first-line treatment of relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).[25] Reports in 2013, showed interim results[26] from a Phase II, open-label, single-arm study designed to evaluate the antitumor activity of brentuximab vedotin in relapsed or refractory CD30-positive NHL, including B-cell neoplasms.[33] The outcome of the trial resulted in a positive recommendation by the Committee for Medicinal Products for Human Use (CHMP) as part of a combination treatment in adults with previously untreated CD30+ stage 3 Hodgkin lymphoma.
Monoclonal antibodyChimericTargetDrugs.comMedlinePlusLicense dataDailyMedPregnancycategoryRoutes ofadministrationIntravenousATC codeL01FX05Legal statusWARNINGCAS NumberDrugBankChemSpiderFormulaMolar massantibody-drug conjugateHodgkin lymphomaanaplastic large cell lymphomaT cellnon-Hodgkin lymphomaSeagenindicatedmaleimidecathepsinvalinecitrullinepara-aminobenzylcarbamateantimitotic agentmonomethyl auristatin Elysosomescathepsin Bcarbamatecaproic acidchemotherapy-induced peripheral neuropathyneutropeniaanemiaupper respiratory tract infectionthrombocytopeniaprogressive multifocal leukoencephalopathyblack box warningFood and Drug Administrationaccelerated approvalbiologics license applicationSeattle GeneticsrelapsedEuropean Medicines Agencymarketing authorizationcutaneous T-cell lymphomamycosis fungoidesclinical trialdiffuse large B-cell lymphomachemotherapydoxorubicinbleomycinvinblastinedacarbazineclassical Hodgkin lymphomavincristinetubulincyclophosphamidehydroxydaunorubicinprednisoneprednisolonepublic domainClinicalTrials.govTargeted cancer therapyantineoplastic agentsmonoclonal antibodiesReceptor tyrosine kinaseHER1/EGFRCetuximabPanitumumabHER2/neuPertuzumabTrastuzumab+hyaluronidaseTrastuzumab emtansineTrastuzumab deruxtecanZanidatamabCatumaxomabEdrecolomabVEGF-ABevacizumabLeukemialymphomalymphoidGlofitamabElranatamabMosunetuzumabIbritumomabObinutuzumabOfatumumabRituximabTositumomabAlemtuzumabmyeloidGemtuzumab ozogamicinAmivantamabAtezolizumabAvelumabAxatilimabBelantamab mafodotinBermekimabBlinatumomabCemiplimabCosibelimabDaratumumabDinutuximab betaDostarlimabDurvalumabElotuzumabEnfortumab vedotinEpcoritamabInotuzumab ozogamicinIpilimumabIsatuximabLoncastuximab tesirineMirvetuximab soravtansineMogamulizumabMoxetumomab pasudotoxNaxitamabNecitumumab